FOSCARNET FOR SUPPRESSION OF HUMAN-IMMUNODEFICIENCY-VIRUS REPLICATION

被引：31

作者：

FLETCHER, CV

COLLIER, AC

RHAME, FS

BENNETT, D

PARA, MF

BEATTY, CC

JONES, CE

BALFOUR, HH

机构：

[1] UNIV MINNESOTA,HLTH SCI CTR,DEPT LAB MED & PATHOL,MINNEAPOLIS,MN 55455

[2] UNIV MINNESOTA,DEPT PHARM PRACTICE,MINNEAPOLIS,MN

[3] UNIV MINNESOTA,DEPT MED,MINNEAPOLIS,MN 55455

[4] UNIV MINNESOTA,DEPT PEDIAT,MINNEAPOLIS,MN 55455

[5] UNIV WASHINGTON,DEPT MED,SEATTLE,WA

[6] OHIO STATE UNIV,DEPT INTERNAL MED,COLUMBUS,OH 43210

[7] FRONTIER SCI TECH RES FDN,SDAC,PHASE SECT 1,BOSTON,MA

来源：

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY | 1994年 / 38卷 / 03期

关键词：

D O I：

10.1128/AAC.38.3.604

中图分类号：

Q93 [微生物学];

学科分类号：

071005 ; 100705 ;

摘要：

The effect of foscarnet against human immunodeficiency virus (HIV) was evaluated in nine HIV-infected individuals; six completed 28 days of induction therapy. The overall mean increase in CD4(+) lymphocytes was 64 cells per mm(3). The mean decline in the HIV antigen concentration was 108 pg/ml (P = 0.03), and suppression was related to systemic foscarnet exposure by a maximum-effect pharmacodynamic model.

引用

收藏

页码：604 / 607

页数：4

相关论文

共 16 条

[1] NEW LOOK AT STATISTICAL-MODEL IDENTIFICATION [J].

AKAIKE, H .

IEEE TRANSACTIONS ON AUTOMATIC CONTROL, 1974, AC19 (06) :716-723

[2] PHARMACOKINETICS OF INTERMITTENTLY ADMINISTERED INTRAVENOUS FOSCARNET IN THE TREATMENT OF ACQUIRED IMMUNODEFICIENCY SYNDROME PATIENTS WITH SERIOUS CYTOMEGALO-VIRUS RETINITIS [J].

AWEEKA, F ;

GAMBERTOGLIO, J ;

MILLS, J ;

JACOBSON, MA .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1989, 33 (05) :742-745

[3] PHARMACOKINETICS OF CONCOMITANTLY ADMINISTERED FOSCARNET AND ZIDOVUDINE FOR TREATMENT OF HUMAN-IMMUNODEFICIENCY-VIRUS INFECTION (AIDS CLINICAL-TRIALS GROUP PROTOCOL-053) [J].

AWEEKA, FT ;

GAMBERTOGLIO, JG ;

VANDERHORST, C ;

RAASCH, R ;

JACOBSON, MA .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1992, 36 (08) :1773-1778

[4] SIMULATION OF LINEAR COMPARTMENT MODELS WITH APPLICATION TO NUCLEAR-MEDICINE KINETIC MODELING [J].

DARGENIO, DZ ;

SCHUMITZKY, A ;

WOLF, W .

COMPUTER METHODS AND PROGRAMS IN BIOMEDICINE, 1988, 27 (01) :47-54

[5] UNDERSTANDING THE DOSE-EFFECT RELATIONSHIP - CLINICAL-APPLICATION OF PHARMACOKINETIC-PHARMACODYNAMIC MODELS [J].

HOLFORD, NHG ;

SHEINER, LB .

CLINICAL PHARMACOKINETICS, 1981, 6 (06) :429-453

[6]

JACOBSON MA, 1988, J INFECT DIS, V158, P862, DOI 10.1093/infdis/158.4.859

[7]

JELLIFFE R W, 1972, Mathematical Biosciences, V14, P17, DOI 10.1016/0025-5564(72)90003-X

[8] INHIBITION OF HUMAN IMMUNODEFICIENCY VIRUS INVITRO BY COMBINATIONS OF 3'-AZIDO-3'-DEOXYTHYMIDINE AND FOSCARNET [J].

KOSHIDA, R ;

VRANG, L ;

GILLJAM, G ;

HARMENBERG, J ;

OBERG, B ;

WAHREN, B .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1989, 33 (05) :778-780

[9] A RANDOMIZED, CONTROLLED TRIAL OF FOSCARNET IN THE TREATMENT OF CYTOMEGALOVIRUS RETINITIS IN PATIENTS WITH AIDS [J].

PALESTINE, AG ;

POLIS, MA ;

DESMET, MD ;

BAIRD, BF ;

FALLOON, J ;

KOVACS, JA ;

DAVEY, RT ;

ZURLO, JJ ;

ZUNICH, KM ;

DAVIS, M ;

HUBBARD, L ;

BROTHERS, R ;

FERRIS, FL ;

CHEW, E ;

DAVIS, JL ;

RUBIN, BI ;

MELLOW, SD ;

METCALF, JA ;

MANISCHEWITZ, J ;

MINOR, JR ;

NUSSENBLATT, RB ;

MASUR, H ;

LANE, HC .

ANNALS OF INTERNAL MEDICINE, 1991, 115 (09) :665-673

[10] DETERMINATION OF PHOSPHONOFORMATE (FOSCARNET) IN BIOLOGICAL-FLUIDS BY ION-PAIR REVERSED-PHASE LIQUID-CHROMATOGRAPHY [J].

PETTERSSON, KJ ;

NORDGREN, T ;

WESTERLUND, D .

JOURNAL OF CHROMATOGRAPHY-BIOMEDICAL APPLICATIONS, 1989, 488 (02) :447-455